In the previous issue, we introduced the first step in the Trio: making risk stratification clear first (A Deep Dive into the "Health Check Upgrade Trio" | ELIXIR-Puente: Why Should a Health Check Upgrade Start with "Risk Stratification"?). After stratification, how should customers manage their health continuously? Where does repurchase come from? In this issue, we focus on one core question: how to start with blood lipids and build a "re-testable" long-term management pathway.

Why do blood lipids need to be "tested all over again"?

Many health check centres have a question: routine health checks already include the four standard lipid items, so why is a deeper version needed? One of the core indicators for assessing cardiovascular risk in clinical practice today is low-density lipoprotein cholesterol (LDL-C). But a key reality is: in a study of 137,000 coronary heart disease patients, more than 54.6% had LDL-C within the normal range. This means that relying only on the standard four lipid items may fail to identify a considerable portion of people at real risk.

The problem is not that LDL-C is "inaccurate", but that it is "not enough". A routine blood lipid test can only answer: whether the overall level is abnormal. It cannot answer the two more critical questions: What is the lipoprotein structure that actually participates in atherosclerosis? What risk type and structural characteristics correspond to the current lipid abnormality? Cardiovascular risk is often hidden in lipoprotein particle structure and subfraction differences.

What is Zhihang™ 14 items?

Zhihang™ 14 items is a deep blood lipid subfraction analysis solution based on nuclear magnetic resonance spectroscopy. It focuses not only on the "total amount", but also systematically decomposes and quantifies lipoprotein particles and their subfractions, upgrading from "macro indicators" to "microstructure".

Through a single tube of blood, 14 items of deep subfraction analysis can be completed, including:

The four standard lipid items: LDL-C, TC, TG, HDL-C;

Deep subfraction analysis (lipoprotein remnant cholesterol RLP-C, apolipoproteins A1 and B, LDL particle concentration, mean LDL particle size, etc.).

Its value lies not in "replacing routine blood lipids", but in "completing the information layer that routine blood lipids cannot cover". The standard four items answer "whether there is an abnormality"; Zhihang™ 14 items answer "where the risk comes from, how to intervene, and whether there has been real improvement". A single test upgrades from "looking at values" to "looking at structure, source, and the essence of risk".

Not just a test, but a "retesting pathway"

If precision stratification solves "seeing the problem clearly", then the more critical capability of Zhihang™ 14 items is: making management sustainable and verifiable. Around the customer's long-term management pathway, Zhihang™ has designed a standardised retesting rhythm: 0 / 6 / 12 months. It corresponds not only to "when to recheck", but also clarifies "why to recheck and how to judge the effect".

① A clear starting point: complete deep subfraction decomposition through a single tube of blood;

② A viable pathway: a standardised 0 / 6 / 12-month retesting rhythm, clarifying when to recheck, why to recheck, and how to judge the effect;

③ Verifiable improvement results: use data to prove whether the intervention is truly effective.

From "checking blood lipids" to "managing blood lipids" — the value of Zhihang™ 14 items lies not in how many more indicators are measured, but in whether it builds a complete management loop: see the structure → define the pathway → verify the effect → continuously optimise.

Applicable scenarios

It can be directly used as: a high-end health check upgrade item: a deep blood lipid analysis module; a core component of an annual blood lipid management package; a corporate chronic disease management solution; a tool for membership repurchase and operation.

First-phase trial package | 20 cases now open for application

Zhihang™ 14 items has been included in the "Health Check Upgrade Trio" trial package:

Content: ELIXIR-Puente + Zhihang™ 14 items + MiMi™ Pro

Trial settlement price: 1,268 RMB per person (combined reference price 6,340 RMB)

Trial scale: 20 cases (fixed combination, not to be split)

How to apply

Reply with [Trio] to book a 15-minute discussion and confirm the cooperation pathway and contact method.

Compliance statement

This product is for health management reference and does not replace clinical diagnosis and treatment. Expressions such as "guarantee / cure / predict compensation / replace doctors" are strictly prohibited. Cooperation must comply with the unified price system: no inversion, no cross-region diversion, and no split sales.

Let blood lipid management move from "looking at indicators" to "looking at structure, direction, and results".

ProteinT / 谱天生物

INNOVATION FOR NEXT GENERATION

ProteinT is a national-level high-tech enterprise focused on the field of precision medicine multi-omics. As the lead unit of the Tianjin Key Laboratory of Clinical Multi-Omics, it took the lead in conducting "gene + protein + metabolism" multi-omics research, and its independently developed proteomics liquid biopsy technology is at an internationally leading level. Core team members come from well-known research institutions at home and abroad, including Yale University, the National Institutes of Health (USA), and the National Center for Protein Sciences. Its R&D pipeline covers common single cancers and pan-cancer types such as liver, lung, gastric, esophageal, colorectal, and pancreatic cancers, and extends to major chronic diseases such as cardiovascular and cerebrovascular diseases, focusing on key research directions including early screening and early diagnosis, recurrence monitoring, and medication guidance. Its Umbrella™ clinical molecular database, with core intellectual property rights, contains more than 100,000 clinical sample records. ProteinT is committed to continuous technological innovation and clinical translation of cutting-edge achievements, advancing precision medicine and exploring the infinite possibilities of human health.